Wedge Vault: Oleo Technologies

Why this Vault exists. Tuesday 13 May is the Budtender discovery call. Oleo is the back-pocket "by the way" wow moment at the end. If Tomas + John see all 16 options before Tuesday, they can pick the angle that fits Richard's actual mood in the room, hybridise on the spot, or hold the deeper assets back for the Tue 20 May close. Every wedge here is engineered to leave Richard with something useful regardless of whether he signs.

The locked recommendation W1 - Regulatory Readiness Package

The 16-wedge comparison matrix scored /20

Each wedge scored on Wow Factor, Allwright leverage, ASAI safety. Total out of 20. Cost is OO build cost (cash out plus opportunity). Time is calendar days from green-light to deliver. "His to keep" verdict reflects whether the asset has standalone value if Richard does not sign a retainer.

Note on scoring. W1 totals 19 out of 20 because it bundles the highest-leverage individual wedges (W2 + W3 + W4 + post-Allwright mockup + ASO audit) into one shippable package. W16 (Big Dawg) trades 1 point of speed for the operational AI wow factor. Anything below 12 is a hold-back for Phase 2, not a wedge entry point.

Why the locked recommendation wins 7 reasons

1. Allwright is the only event Richard cannot ignore. The Allwright Review timing is the structural hinge of his entire 24-month plan. Every other wedge sits inside that frame. W1 makes us the agency that already understood that on Tuesday.
2. The 74-patient reality is in the package, not denied. Most agencies would pitch volume. We pitch readiness. The Readiness Package treats 74 patients as the operational truth, and the 22 historic consultants as the actual lever. That is the room Richard is already in.
3. The 22-consultant map is an asset only an Irish-MCAP-aware shop can produce. No UK agency knows it exists. No Irish digital agency knows MCAP exists. The map alone signals we read his world before the call.
4. 70 percent of historic prescribers stopped after one patient. That is the operational bottleneck Richard lives in. The Readiness Package answers it directly with the prescriber-only landing page, the CME FAQ structure, and the re-engagement asset per consultant.
5. ASAI 7th edition is treated as a feature, not a constraint. Every page in W1 is HCP-gated, factual-pathway only, no induced demand. We design within Misuse of Drugs Regs 2017, ASAI 7th, GDPR DPIA, and MDR all at once. Most agencies cannot navigate one of those, let alone four.
6. Bedrocan supply is the trust signal we amplify, not co-brand. The provenance microsite (W13) lives inside W1's schema layer. Pharmaceutical-grade cultivation, GMP, cold chain into Cork - factual provenance beats co-branded promotion under ASAI rules.
7. OleoCare is a dormant data goldmine. The app-listing audit inside W1 is the cheapest activation of Oleo's most strategic asset. Once OleoCare data depth grows, every subsequent wedge (W7, W17 post-Allwright outcome reports, W21 truMED port) plugs into the same patient pool.
8. The post-Allwright mockup is the close. Richard sees the homepage of oleo.ie the morning eligibility expands. That is the picture he holds for the next 30 days. Every other wedge is a story; the mockup is a screen he can show Shirley.

Why not the others 15 short answers

Hybrid combinations 6 named stacks

If the boys see the menu, they will combine. Below are the six hybrids worth pre-naming. Each has a cost, a time-to-ship, the signal it sends, and the room-temperature it wins in.

Alternative angles + marketing pitches 5 framings

Gold and gems 28 non-obvious insights

Regulatory edges

1. Allwright Review is the only event Richard cannot ignore. Every other wedge sits inside that frame. The agency that read this on Tuesday wins.
2. ASAI 7th edition treats prescription products differently from OTC. No induced demand for a prescription medicine. HCP-gated content is fully compliant. Most agencies pitch generic SEO and trip ASAI on day one.
3. HPRA pharmacovigilance reporting is quarterly. An AI agent that pre-fills the quarterly returns saves measurable hours and is the highest-leverage internal hire Oleo can make without growing headcount.
4. Misuse of Drugs Regs 2017 narrows what can be advertised, not what can be educated. Pathway content, factual provenance, HCP-gated education are all compliant. The compliance moat is the marketing moat.

Market gems

1. 74 patients ever. That is the entire MCAP cohort to date. Volume builds against UK datasets are not credible until depth grows.
2. 22 historic consultants. The known universe of Irish doctors who have ever written an MCAP script. The list is small enough to re-engage one by one.
3. Roughly 70 percent of historic prescribers stopped after one patient. That is the operational truth. Re-activation is cheaper than acquisition.
4. Curaleaf Belfast is leaking ROI patients via NI cross-border. Cross-border collection on a UK private clinic prescription is a real demand signal Oleo currently does not capture.
5. UK private clinic market validates ~6,000-patient Irish potential. Pro-rata UK metrics on a population basis put Ireland's post-eligibility-expansion ceiling near 80x today's volume.

Asset gems

1. Bedrocan supply is the highest-trust pharmaceutical-grade signal in Irish cannabis. Pharmaceutical-grade cultivation, GMP, cold chain into Cork. No competitor has a comparable provenance story.
2. OleoCare app is a dormant patient-data goldmine. Anonymised aggregated outcomes are the path to Ireland's only published real-world MCAP dataset.
3. Medical Cannabis ID Card is an under-utilised brand asset. Extending the card into a verified-patient portal compounds the patient-side moat at near-zero cost.
4. The 10-page expansion-ready architecture is reusable. Same schema spine carries across all current and future MCAP-eligible conditions, which is why W1 scales without rework.

Cross-property gems

1. truMED truPRO + truME bot pattern is port-ready. Provider-facing bot for protocol queries plus patient-facing bot for adherence prompts maps cleanly onto MCAP without re-architecture.
2. Olio.com is parked but the entity layer can be built now while it is cheap. Wikidata Q-item, founder-network articles, topic cluster - the entity work is cheaper today than the day Olio.com unparks.
3. Wins on Oleo compound onto Budtender. Medical-grade brand credibility flows downhill into the consumer brand. Reverse does not work.
4. Three properties under one architecture is rare in Irish cannabis. No competitor runs medical, consumer, and operational stacks under one roof. The architecture itself is the moat.

Founder gems

1. Richard's medtech background plus Shirley CTO co-founder is rare. 25 years Applied Medical, Creco exit, truMED EU ops. Shirley as full CTO partner. The co-founder pair signal is unique in Irish cannabis.
2. Celadon Pharma board contact is a downstream rail. Public-market UK cannabis pharma board exposure gives Richard a UK trade voice most Irish founders do not have.
3. Richard already runs the dual-track playbook at truMED. Generic SEO pitches will land flat. He knows what good looks like. The Readiness Package is engineered to clear his quality bar in the first 60 seconds.

Competitor gems

1. Tilray entering IE-UK in 2026. Per the market dive, Tilray (now owns Lyphe + Mamedica post-2026 acquisition) is the single biggest post-Allwright competitor. They will out-supply on price and SKU breadth within 12 months.
2. UK private clinic prescription with cross-border collection is leaking demand. Mamedica + Sapphire + Lyphe-now-Tilray have battle-tested patient acquisition. Ireland will see direct entry through this channel.
3. Bedrocan supply ceiling is structural risk. Germany hit a 122-tonne import cap in September 2025. If Allwright opens Irish demand, supply becomes the constraint, not demand. Second supplier or capped.

Operational gems

1. 74 patients cannot justify volume builds today. Pharmacy ordering portals, multi-supplier APIs, large content libraries are Phase 2. Pre-Allwright is about positioning, not volume infrastructure.
2. HPRA AI removes ops headcount as the constraint. The operational ceiling is paperwork, not demand. Automating quarterly returns is more valuable than any marketing campaign.
3. Class IIa MDR confirmation unlocks Panacea EU sales. Until MDR is confirmed, Panacea is a B2B device with no EU distribution channel. After, it is a 27-country addressable market.

Compliance gems

1. Every wedge respects four overlapping regulatory frames. Misuse of Drugs Regs 2017, ASAI Code 7th edition, GDPR DPIA on OleoCare data, MDR on Panacea. This is the moat. Most agencies cannot navigate one of those, let alone four together.
2. Patient testimonials with PV signal capture are compliant. Done as pharmacovigilance signal collection rather than promotional quotes, real-name testimonials are usable as Allwright submission evidence and as ASAI-safe content.
3. Co-branding with Bedrocan is ASAI-risky; provenance is ASAI-safe. The factual supply story is publishable. Joint-marketing is not. The microsite must be carefully framed - and we know exactly how to frame it.

Live-room decision tree Tomas + John on the call

Use this if Richard surfaces specific signals during the Tuesday "by the way" moment or on the close call. Each branch maps a verbal cue to a concrete next step.

Execution-ready appendix - W1 ship-7-day schedule if Richard says go

Day-by-day plan to deliver the locked W1 Regulatory Readiness Package. Every day has a single deliverable, an owner, and an acceptance check before the next day starts.

Acceptance criteria for "done"

What could go wrong

Cross-links all roads

Wedge Vault: Oleo Technologies · v1 · 2026-05-08 · Internal only · Tomas + John + Donal